The study of new immunotherapeutic agent DF19001 for HDM allergic rhinitis patients

illustrative image

The research company RAPHAS is conducting the clinical trial Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients.

When administering clinical trial drugs to patients with house dust mite allergic rhinitis, safety/tolerance is comparatively evaluated as the primary outcome, and symptom improvement and immune activity of the disease are comparatively evaluated as secondary outcome.

It is planned to include 54 participants.

Actual study start date is January 20, 2022. The researchers expect to complete the study by June 15, 2025.

One primary outcome measure is systemic adverse event, Systemic adverse reaction evaluation was evaluated according to the WAO subcutaneous immunotherapy systemic reaction grading system.

Further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT05525650.

Clinical Research News

Upcoming Clinical Trials

3